The aim of this document is to provide general information about breast scintigraphy in patients with known or suspected breast cancer. The corresponding guidelines of the Society of Nuclear Medicine SNM have been taken into consideration and partially integrated with the present text. It describes only the?99mTc-SestaMIBI(2-methoxyisobutiylisonitrile) and the?99mTc-Tetrofosmin (1,2-bis bis(2-ethoxy-ethylphosphine)ethane) breast scintigraphy protocols used in the current clinical routine.
